Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531667 | 0.79 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL8290760 | 0.79 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL211919 | 0.77 | PNMT (0.48) | IDO1ALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL2089246 | 0.77 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL17552707 | 0.77 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL13647058 | 0.77 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL697564 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL2764669 | 0.77 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL7538168 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19RAB9A | |
| SCHEMBL622259 | 0.77 | ALDH1A1 (0.41) | IDO1ALDH1A1SMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763164-B | Preparation method and application of ortho-carbonyl amino substituted benzene derivatives | 中国医学科学院药物研究所 | 2023-03-10 | — | — | CN | disclosed |
| CN-111763164-A | Preparation method and application of ortho-carbonyl amino substituted benzene derivatives | 中国医学科学院药物研究所 | 2020-10-13 | — | — | CN | disclosed |
| WO-2020199945-A1 | ORTHO-CARBONYL AMINO-SUBSTITUTED BENZENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国医学科学院药物研究所 | 2020-10-08 | — | — | WO | disclosed |
| CN-102670503-A | Stable emulsion composition | TAKEDA PHARMACEUTICAL | 2012-09-19 | — | — | CN | disclosed |
| EP-2094643-B1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1209149-B9 | SUBSTITUTED AROMATIC-RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-2255785-A2 | Stable emulsion composition | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1209149-B1 | SUBSTITUTED AROMATIC-RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-7417059-B2 | Substituted aromatic-ring compounds, process for producing the same and use | TAKEDA PHARMACETICAL COMPANY LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| WO-2002067913-A1 | (Z)-STYRYLBENZYLSULFONES AND PHARMACEUTICAL USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1209149-A1 | SUBSTITUTED AROMATIC-RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-0711760-B1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL IND LTD (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-0882720-B1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-6130332-A | USING A GROUP 8 METAL CATALYST AND ALDEHYDES OR KETONE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-10 | — | — | US | disclosed |
| US-6127538-A | HYDROXYALKYLATION OF A TRIAMINO TRIAZINE DERIVATIVE HAVING AT LEAST ONE REACTIVE NITROGEN BY REACTING WHILE HEATING WITH AN ALKANEDIOL OR ITS ADDUCT IN THE PRESENCE OF HYDROGEN AND A METAL CATALYST; BY-PRODUCT INHIBITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0882720-A1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5792867-A | Method of alkylating of triazine derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0711760-A1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | LIPA, PHOSPHO1, CEL | IDO1 1969/4885ALDH1A1 974/4885SMN1; SMN2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.